Follow-up on corrections·February 20, 2026

Licensing Program Analyst (LPA) Alvaro Ramirez, Jr made an unannounced case management visit in conjunction with Unusual Incident/Injury Report (UIIR) dated January 14, 2026. LPA was greeted and granted entry by Executive Director (ED) Kathleen Olson. LPA explained the reason for the visit. Per UIIR, as of December 12, 2025, Resident 1 (R1) had an order to take Valganciclovir HCI 450 mg 1 tablet twice a day for 14 days. Per UIIR, on December 27, 2025, order was decreased to Valganciclovir 450 mg 1 tablet once daily and discontinued on EMAR. Per UIIR, R1 did not receive the medication for 17 days. During today's visit LPA reviewed the Physician's orders dated December 10, 2025, for R1. Per Physician's orders under instructions it states restart valcyte 450 mg 1 tab x 14 days then decrease to 1 tab daily starting December 27, 2025. Per Physician's orders dated January 13, 2026, R1 was prescribed Valganciclovir 450 mg 1 tab po bid x 14 days then decrease to 1 tab po daily starting January 28, 2026. Per UIIR, the medication was restarted on January 13, 2026. A Health and Safety inspection was conducted, and LPA Ramirez observed no Health and Safety concerns during today's visit. Based on observations and records reviewed during today’s inspection, one deficiency is being cited per Title 22 Division 6 of the California Code of Regulations. An exit interview was conducted with ED Olson and a copy of this report and Appeal Rights were provided at the time of exit.